Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University of Illinois Chicago: Clinical Trials & FDA Approval Profile

University of Illinois Chicago (Global / Institutional) sponsors 37 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 25 active protocols (18 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)13.5%
Median Closed Enrollment vs National (145 pts)39 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University of Illinois Chicago
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)37
Active Pipeline (Recruiting Now)25 (18)
Completed vs Stopped Early7 / 5 (13.5%)
Median Closed Actual Enrollment39 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With University of Illinois Chicago
Hospital Research SiteLocationShared Protocols
University of IllinoisChicago, IL5

Explore interactive annual charts and M&A subsidiary rollups in the University of Illinois Chicago Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI